- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Benralizumab, mepolizumab and omalizumab for treating severe asthma
Drug guidance
Benralizumab, mepolizumab and omalizumab for treating severe asthma
Condition
Respiratory
1 September 2020
Published on 01 Sep 2020
Last Updated on 01 Sep 2020
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing:
Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma; and
Omalizumab on the MAF for treating severe allergic asthma
due to unacceptable cost-effectiveness at the prices proposed by the manufacturers.
Benralizumab, mepolizumab and omalizumab for treating severe asthma (1 Sept 2020) [PDF, 239 KB]
Benralizumab and mepolizumab for treating severe eosinophilic asthma PES (1 Sept 2020) [PDF, 107 KB]
Omalizumab for treating severe allergic asthma PES (1 Sept 2020) [PDF, 107 KB]